Literature DB >> 26426969

Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.

Haiping Liu1, Ping Chen, Kristen Wroblewski, Peng Hou, Chen-Peng Zhang, Yulei Jiang, Yonglin Pu.   

Abstract

OBJECTIVES: The objective of this study was to test the hypothesis that the metabolic tumor volume (MTV) of primary non-small-cell lung cancer is not sensitive to differences in F-fluorodeoxyglucose (F-FDG) uptake time, and to compare this consistency of MTV measurements with that of standardized uptake value (SUV) and total lesion glycolysis (TLG).
METHODS: Under Institutional Review Board approval, 134 consecutive patients with histologically proven non-small-cell lung cancer underwent F-FDG PET/computed tomography scanning at about 1 h (early) and 2 h (delayed) after intravenous injection of F-FDG. MTV, SUV, and TLG of the primary tumor were all measured. Student's t-test and Wilcoxon's signed-rank test for paired data were used to compare MTV, SUV, and TLG between the two scans. The intraclass correlation coefficient (ICC) was used to assess agreement in PET parameters between the two scans and between the measurements made by two observers.
RESULTS: MTV was not significantly different (P=0.17) between the two scans. However, SUVmax, SUVmean, SUVpeak, and TLG increased significantly from the early to the delayed scans (P<0.0001 for all). The median percentage change between the two scans in MTV (1.65%) was smaller than in SUVmax (11.76%), SUVmean(10.57%), SUVpeak(13.51%), and TLG (14.34%); the ICC of MTV (0.996) was greater than that of SUVmax (0.933), SUVmean (0.952), SUVpeak (0.928), and TLG (0.982). Interobserver agreement between the two radiologists was excellent for MTV, SUV, and TLG on both scans (ICC: 0.934-0.999).
CONCLUSION: MTV is not sensitive to common clinical variations in F-FDG uptake time, its consistency is greater than that of SUVmax, SUVmean, SUVpeak, and TLG, and it has excellent interobserver agreement.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26426969      PMCID: PMC4654972          DOI: 10.1097/MNM.0000000000000396

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  31 in total

1.  Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Yonglin Pu
Journal:  Acta Radiol       Date:  2012-06-01       Impact factor: 1.990

2.  Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Hao Zhang; Kenji Suzuki; Yonglin Pu
Journal:  Acad Radiol       Date:  2012-01       Impact factor: 3.173

3.  Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.

Authors:  Keunyoung Kim; Seong-Jang Kim; In-Joo Kim; Yun Seong Kim; Kyoungjune Pak; Heeyoung Kim
Journal:  Nucl Med Commun       Date:  2012-06       Impact factor: 1.690

4.  Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Authors:  Jong-Ryool Oh; Ji-Hyoung Seo; Ari Chong; Jung-Joon Min; Ho-Chun Song; Young-Chul Kim; Hee-Seung Bom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

5.  Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.

Authors:  Percy Lee; Jose G Bazan; Philip W Lavori; Dilani K Weerasuriya; Andrew Quon; Quynh-Thu Le; Heather A Wakelee; Edward E Graves; Billy W Loo
Journal:  Clin Lung Cancer       Date:  2011-06-24       Impact factor: 4.785

6.  Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Shengri Liao; Rony Kampalath; Bill C Penney; Yi Zhang; Yonglin Pu
Journal:  Acad Radiol       Date:  2012-09-19       Impact factor: 3.173

7.  What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom.

Authors:  Maria Werner-Wasik; Arden D Nelson; Walter Choi; Yoshio Arai; Peter F Faulhaber; Patrick Kang; Fabio D Almeida; Ying Xiao; Nitin Ohri; Kristin D Brockway; Jonathan W Piper; Aaron S Nelson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-29       Impact factor: 7.038

8.  Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.

Authors:  Helen H W Chen; Nan-Tsing Chiu; Wu-Chou Su; How-Ran Guo; Bi-Fang Lee
Journal:  Radiology       Date:  2012-06-12       Impact factor: 11.105

9.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.

Authors:  Christophe Van de Wiele; Vibeke Kruse; Peter Smeets; Mike Sathekge; Alex Maes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

10.  Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.

Authors:  Seung Hyup Hyun; Joon Young Choi; Kwhanmien Kim; Jhingook Kim; Young Mog Shim; Sang-Won Um; Hojoong Kim; Kyung-Han Lee; Byung-Tae Kim
Journal:  Ann Surg       Date:  2013-02       Impact factor: 12.969

View more
  6 in total

1.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

2.  Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.

Authors:  Yonglin Pu; James X Zhang; Haiyan Liu; Daniel Appelbaum; Jianfeng Meng; Bill C Penney
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-07       Impact factor: 9.236

3.  Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.

Authors:  Xuee Zhu; Chuanhong Liao; Bill C Penney; Feng Li; Mark K Ferguson; Cassie A Simon; Tianming Wu; Haiyan Liu; Yonglin Pu
Journal:  Nucl Med Commun       Date:  2017-02       Impact factor: 1.690

4.  18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods.

Authors:  Esther Mena; Sara Sheikhbahaei; Mehdi Taghipour; Abhinav K Jha; Esther Vicente; Jennifer Xiao; Rathan M Subramaniam
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

5.  Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.

Authors:  Suman Shrestha; Tetsuya Higuchi; Katsuyuki Shirai; Azusa Tokue; Shreya Shrestha; Jun-Ichi Saitoh; Hiromi Hirasawa; Tatsuya Ohno; Takashi Nakano; Yoshito Tsushima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-22       Impact factor: 9.236

6.  Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study.

Authors:  Do Hyoung Lim; Jai Hyuen Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.